HNGE vs HUMA: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

HNGE is the larger of the two ($9.80B market cap): the incumbent the market prices for continued execution (37.32x forward earnings). HUMA is the smaller challenger ($156.82M), priced similarly on forward earnings (-2.28x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

HNGE vs HUMA: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricHNGEHUMAWhat it tells you
Market cap$9.80B$156.82MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E37.32-2.28Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Price vs 52-week range96% of range19% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book32.815.00How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how HNGE and HUMA affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HNGE and HUMA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HNGE and HUMA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Hinge Health (HNGE) do?

Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. The company's core offering combines a mobile and connected-sensor app with personalized exercise therapy programs, behavioral health support, and access to physical therapists, plus care navigation for surgery decisions. Customers are primarily large employers and health plans that purchase Hinge Health benefits for their members.

Full HNGE guide

What does Humacyte (HUMA) do?

Humacyte, Inc. is a regenerative-medicine company that manufactures bioengineered human tissue. Its core platform grows acellular tissue engineered vessels (ATEVs) by seeding human vascular cells onto a biodegradable scaffold in a bioreactor, then washing the cells away to leave a non-living, off-the-shelf vessel that a surgeon can implant without the immune rejection or wait associated with a patient's own vein. The lead product, Symvess (acellular tissue engineered vessel-tyod), is approved as a vascular conduit for adults with extremity arterial injury who need urgent revascularization to avoid imminent limb loss when a vein graft is not feasible.

Full HUMA guide

HNGE vs HUMA: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • HNGE drivers: Employer benefit penetration; Surgery prevention as ROI driver.
  • HUMA drivers: First-mover bioengineered vessel; Pipeline beyond trauma.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Digital health categories are competitive with various platforms targeting MSK and other condition areas, including the well-funded private Sword Health. For HUMA, the risks are substantial and concentrated.

HNGE or HUMA: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick HNGE if you believe its drivers more; HUMA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HNGE and HUMA guides.

HNGE vs HUMA: the full fundamentals

HNGE. Hinge Health's valuation has moved from a story about reaching profitability to one about sustaining fast, profitable growth. At about 33x trailing and forward earnings and 11x sales after a ~123% year-to-date gain, the shares sit just below the ~$112 average analyst target, so the November 2 third-quarter report (consensus ~$0.60 EPS on ~$224.8 million of revenue) will be read for whether growth near 50% can hold.

HUMA. An early-commercial biotech like Humacyte cannot be valued on earnings, because there are none; it trades on the option value of a ramping product and an expanding pipeline weighed against cash burn and dilution. At about $0.45 a share the market values the company near $125 million, well below its mid-2026 level, and the mean analyst target of about $1.62 shows how wide expectations run. The relevant questions are how fast Symvess revenue scales toward the cash-burn rate, how much new stock must be issued before that happens, and what the dialysis-access program could be worth if approved; Q3 results are expected around November 12.

Headline figures (approximate, October 2026): HNGE shows revenue (ttm) ~$720 million; Q2 2026 ~$212.8 million, up ~53% year over year, gross / operating margin ~85% / ~19%, net income (ttm) ~$107 million (Q2 2026 ~$43.1 million), adjusted eps (q2 2026) ~$0.59 vs ~$0.62 estimate; HUMA shows revenue (ttm) ~$2.1 million, revenue (q2 2026) ~$0.4 million, net loss (ttm / q2 2026) ~$97 million / ~$36.8 million, operating cash used (ttm) ~$97 million.

The bottom line: HNGE vs HUMA

HNGE and HUMA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HNGE and HUMA exposure against your real portfolio. It is not an investment adviser.

Wondering how HNGE or HUMA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Hinge Health

Ask Walnut's AI anything about HNGE and see how it fits what you own.

FAQ

What is the difference between HNGE and HUMA?

+

Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. Humacyte, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is HNGE or HUMA the better stock?

+

Neither is universally better. HNGE is the larger incumbent; HUMA is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, HNGE or HUMA?

+

On forward P/E (as of November 2026), HNGE trades at 37.32x and HUMA at -2.28x, so HUMA is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both HNGE and HUMA?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of HNGE vs HUMA?

+

HNGE: Digital health categories are competitive with various platforms targeting MSK and other condition areas, including the well-funded private Sword Health. Employer benefits cycle and economic pressure can slow new logo growth. Member engagement determines outcomes and ROI to customers; engagement scaling must continue. Valuation is now the most visible risk: after a ~100% one-year gain the stock trades around 33x trailing earnings, 11x sales and 24x book value as of October 2026, so a revenue deceleration or another small EPS miss like Q2 2026 (~$0.59 versus ~$0.62 expected) could move the shares sharply. Recent IPO dynamics persist, with continuing insider sales, including a ~$20.6 million sale disclosed in October 2026, adding supply and shaping sentiment. HUMA: The risks are substantial and concentrated. The commercial ramp for Symvess is unproven and has started slowly, so revenue remains negligible relative to spending: Q2 2026 revenue was about $0.4 million against a $36.8 million net loss, and the per-share loss of $0.16 missed the $0.10 estimate. Humacyte burns cash heavily, with trailing operating cash outflow near $97 million, and management has disclosed substantial doubt about its ability to continue as a going concern without stronger sales or new financing. Funding that gap has meant repeated stock offerings that dilute existing shareholders, including raises in 2026. The share price, near $0.45, sits below Nasdaq's $1 minimum bid requirement, which could become a listing issue if it persists. The pipeline carries clinical and regulatory risk: planned dialysis-access and peripheral-artery filings could be delayed or rejected. Symvess also carries a boxed warning for graft failure, including rupture. And the company faces competition from established vascular grafts and standard surgical options, plus the broad adoption hurdle of getting hospitals to pay a premium for a new technology.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell HNGE or HUMA; figures are approximate and dated (as of November 2026). Verify current data before investing.